A foundation that gives the Charles Rodolphe Brupbacher Prize for Cancer Research every two years to a scientist who has made extraordinary contributions to basic cancer research, with a scientific symposium in Zurich.
The Charles Rodolphe Brupbacher Foundation was set up by Frédérique Brupbacher in memory of her husband, Charles Rodolphe Brupbacher, who died of cancer; she presided over it until her death in 2015. Its seat is in Vaduz, Liechtenstein, and in scientific matters it works with the University of Zurich and its Medical Faculty.
Every two years it gives the Charles Rodolphe Brupbacher Prize for Cancer Research to a scientist who has made extraordinary contributions to basic oncological research, holds the scientific C. R. Brupbacher Symposium in Zurich, gives up to five Young Investigator Awards and arranges a public lecture in German. Its laureates page lists prizes from 1993 to 2019, beginning with Arnold Levine and David Lane, who lectured on p53; later laureates include Brian Druker (2001), Harald zur Hausen (1999), Richard Peto and Nubia Muñoz (2009), Bert Vogelstein (2011), Irving Weissman (2015), Laurence Zitvogel (2017) and Michael N. Hall (2019). The foundation's site gives no date yet for the 15th symposium.
Immunologist who showed that the gut microbiome shapes responses to immunotherapy and chemotherapy.
Isolated the first blood stem cells and discovered the 'don't eat me' signal CD47 on cancer cells.
Bert Vogelstein is the most-cited scientist in cancer genetics: he mapped how colorectal cancer develops and founded the field of cancer genome sequencing and blood-based detection.
Epidemiologist who quantified how smoking kills and invented the meta-analysis methods that established adjuvant cancer therapy.
Colombian epidemiologist whose IARC studies proved HPV causes cervical cancer and identified the types the vaccines target.
Proposed cancer immunoediting and showed neoantigens are the targets of checkpoint immunotherapy.
He pushed a shelved kinase inhibitor through the laboratory and into a 1998 trial when few believed a targeted pill could work. Imatinib made chronic myeloid leukaemia a disease people live with, and became the model for targeted therapy.
Against the consensus that herpes was to blame, he proposed in 1976 that papillomaviruses cause cervical cancer and isolated HPV16 and HPV18 from tumours in 1983-84, making vaccination and HPV testing possible. Nobel Prize 2008.
Shares Royal Swedish Academy of Sciences, King Faisal Foundation, Pezcoller Foundation, Lasker Foundation.
Shares King Faisal Foundation, Brian Druker, Lasker Foundation.
Shares Pezcoller Foundation, Lasker Foundation.
Shares Harald zur Hausen, Lasker Foundation.
Shares Brian Druker, Lasker Foundation.
Shares Robert D. Schreiber, Harald zur Hausen.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/